{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:23:42Z","timestamp":1790659422668,"version":"4.1.0"},"reference-count":175,"publisher":"Spandidos Publications","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2026.15497","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T12:40:42Z","timestamp":1771936842000},"page":"1-18","source":"Crossref","is-referenced-by-count":4,"title":["Histone deacetylases: Function in tumor development and therapeutic prospects (Review)"],"prefix":"10.3892","volume":"31","author":[{"given":"Runling","family":"Lin","sequence":"first","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, School of Basic Medicine, Shandong Second Medical University, Weifang, Shandong 261000, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, School of Basic Medicine, Shandong Second Medical University, Weifang, Shandong 261000, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, School of Basic Medicine, Shandong Second Medical University, Weifang, Shandong 261000, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, School of Basic Medicine, Shandong Second Medical University, Weifang, Shandong 261000, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2026,2,24]]},"reference":[{"key":"key20260417093325_b1-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.4161\/auto.6.8.13365","article-title":"Autophagy potentiates the anti-cancer effects of the histone deacetylase inhibitors in hepatocellular carcinoma","volume":"6","author":"Liu","year":"2010","journal-title":"Autophagy"},{"key":"key20260417093325_b2-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"7841","DOI":"10.3390\/ijms25147841","article-title":"The epigenetic modifiers HDAC2 and HDAC7 inversely associate with cancer stemness and immunity in solid tumors","volume":"25","author":"Maciejewski","year":"2024","journal-title":"Int J Mol Sci"},{"key":"key20260417093325_b3-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"102262","DOI":"10.1016\/j.clgc.2024.102262","article-title":"Transcriptome-based network analysis related to histone deacetylase genes and identified EMP1 as a potential biomarker for prognosis in bladder cancer","volume":"23","author":"Bao","year":"2025","journal-title":"Clin Genitourin Cancer"},{"key":"key20260417093325_b4-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1016\/j.apsb.2023.02.007","article-title":"Targeting histone deacetylases for cancer therapy: Trends and challenges","volume":"13","author":"Liang","year":"2023","journal-title":"Acta Pharm Sin B"},{"key":"key20260417093325_b5-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1080\/17446651.2023.2183840","article-title":"HDACs as an emerging target in endocrine tumors: A comprehensive review","volume":"18","author":"Klieser","year":"2023","journal-title":"Expert Rev Endocrinol Metab"},{"key":"key20260417093325_b6-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"960263","DOI":"10.3389\/fgene.2022.960263","article-title":"Histone deacetylases modulate resistance to the therapy in lung cancer","volume":"13","author":"Contreras-Sanz\u00f3n","year":"2022","journal-title":"Front Genet"},{"key":"key20260417093325_b7-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"585452","DOI":"10.3389\/fonc.2020.585452","article-title":"Mechanism and molecular network of RBM8A-mediated regulation of oxaliplatin resistance in hepatocellular carcinoma","volume":"10","author":"Liang","year":"2021","journal-title":"Front Oncol"},{"key":"key20260417093325_b8-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"6600","DOI":"10.3390\/ijms26146600","article-title":"Valproic acid reduces invasiveness and cellular growth in 2D and 3D glioblastoma cell lines","volume":"26","author":"Giordano","year":"2025","journal-title":"Int J Mol Sci"},{"key":"key20260417093325_b9-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1007\/s12672-024-01018-9","article-title":"Elevated histone deacetylase 10 expression promotes the progression of clear cell renal cell carcinoma by notch-1-PTEN signaling axis","volume":"15","author":"Zheng","year":"2024","journal-title":"Discov Oncol"},{"key":"key20260417093325_b10-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1158\/1078-0432.CCR-22-2085","article-title":"Pharmacological landscape of FDA-approved anticancer drugs reveals sensitivities to ixabepilone, romidepsin, omacetaxine, and carfilzomib in aggressive meningiomas","volume":"29","author":"Jungwirth","year":"2023","journal-title":"Clin Cancer Res"},{"key":"key20260417093325_b11-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1038\/s12276-021-00659-y","article-title":"Phospholipase D2 is a positive regulator of sirtuin 1 and modulates p53-mediated apoptosis via sirtuin 1","volume":"53","author":"Lee","year":"2021","journal-title":"Exp Mol Med"},{"key":"key20260417093325_b12-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"4574","DOI":"10.7150\/thno.86928","article-title":"Histone deacetylase-mediated tumor microenvironment characteristics and synergistic immunotherapy in gastric cancer","volume":"13","author":"Lin","year":"2023","journal-title":"Theranostics"},{"key":"key20260417093325_b13-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/nrg2485","article-title":"The many roles of histone deacetylases in development and physiology: Implications for disease and therapy","volume":"10","author":"Haberland","year":"2009","journal-title":"Nat Rev Genet"},{"key":"key20260417093325_b14-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1080\/1062936X.2022.2145353","article-title":"A quantitative structural analysis of AR-42 derivatives as HDAC1 inhibitors for the identification of promising structural contributors","volume":"33","author":"Kundu","year":"2022","journal-title":"SAR QSAR Environ Res"},{"key":"key20260417093325_b15-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13046-022-02266-9","article-title":"HDAC7 promotes NSCLC proliferation and metastasis via stabilization by deubiquitinase USP10 and activation of \u03b2-catenin-FGF18 pathway","volume":"41","author":"Guo","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"key20260417093325_b16-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"20230665","DOI":"10.1515\/med-2023-0665","article-title":"HDAC5-mediated PRAME regulates the proliferation, migration, invasion, and EMT of laryngeal squamous cell carcinoma via the PI3K\/AKT\/mTOR signaling pathway","volume":"18","author":"Yu","year":"2023","journal-title":"Open Med (Wars)"},{"key":"key20260417093325_b17-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41419-022-05522-0","article-title":"HDAC7\/c-Myc signaling pathway promotes the proliferation and metastasis of choroidal melanoma cells","volume":"14","author":"Zhang","year":"2023","journal-title":"Cell Death Dis"},{"key":"key20260417093325_b18-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1038\/s43018-024-00816-y","article-title":"Phase separation of phospho-HDAC6 drives aberrant chromatin architecture in triple-negative breast cancer","volume":"5","author":"Lu","year":"2024","journal-title":"Nat Cancer"},{"key":"key20260417093325_b19-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41586-024-08248-5","article-title":"Human HDAC6 senses valine abundancy to regulate DNA damage","volume":"637","author":"Jin","year":"2025","journal-title":"Nature"},{"key":"key20260417093325_b20-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"643","DOI":"10.4161\/auto.5050","article-title":"HDAC6 at the intersection of autophagy, the ubiquitin-proteasome system and neurodegeneration","volume":"3","author":"Pandey","year":"2007","journal-title":"Autophagy"},{"key":"key20260417093325_b21-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"3679","DOI":"10.1007\/s11030-025-11217-3","article-title":"First report on analysis of chemical space, scaffold diversity, critical structural features of HDAC11 inhibitors","volume":"29","author":"Bhagat","year":"2025","journal-title":"Mol Divers"},{"key":"key20260417093325_b22-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1038\/s41417-022-00452-7","article-title":"HDAC11 activity contributes to MEK inhibitor escape in uveal melanoma","volume":"29","author":"Sriramareddy","year":"2022","journal-title":"Cancer Gene Ther"},{"key":"key20260417093325_b23-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"2910","DOI":"10.1182\/blood-2010-08-303701","article-title":"HDAC11 plays an essential role in regulating OX40 ligand expression in Hodgkin lymphoma","volume":"117","author":"Buglio","year":"2011","journal-title":"Blood"},{"key":"key20260417093325_b24-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"270","DOI":"10.2174\/0115734099282303240126061624","article-title":"Exploration of fingerprints and data mining-based prediction of some bioactive compounds from Allium sativum as histone deacetylase 9 (HDAC9) inhibitors","volume":"21","author":"Das","year":"2025","journal-title":"Curr Comput Aided Drug Des"},{"key":"key20260417093325_b25-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1172\/JCI69738","article-title":"New and emerging HDAC inhibitors for cancer treatment","volume":"124","author":"West","year":"2014","journal-title":"J Clin Invest"},{"key":"key20260417093325_b26-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12032-024-02553-9","article-title":"Dissecting the epigenetic orchestra of HDAC isoforms in breast cancer development: A review","volume":"42","author":"Debbarma","year":"2024","journal-title":"Med Oncol"},{"key":"key20260417093325_b27-ol-31-4-15497","first-page":"324","article-title":"Histone deacetylase inhibitors, intrinsic and extrinsic apoptotic pathways, and epigenetic alterations of histone deacetylases (HDACs) in hepatocellular carcinoma","volume":"20","author":"Sanaei","year":"2021","journal-title":"Iran J Pharm Res"},{"key":"key20260417093325_b28-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1097\/HEP.0000000000000875","article-title":"Nuclear KRT19 is a transcriptional corepressor promoting histone deacetylation and liver tumorigenesis","volume":"81","author":"Han","year":"2025","journal-title":"Hepatology"},{"key":"key20260417093325_b29-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1007\/s12013-024-01587-0","article-title":"Histone deacetylases (HDACs) roles in inflammation-mediated diseases; current knowledge","volume":"83","author":"Jasim","year":"2025","journal-title":"Cell Biochem Biophys"},{"key":"key20260417093325_b30-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"3183","DOI":"10.1038\/s41388-025-03471-4","article-title":"HDAC1\/2-mediated deacetylation of KLF9 promotes the malignant progression of nasopharyngeal carcinoma via CDH17","volume":"44","author":"Zhang","year":"2025","journal-title":"Oncogene"},{"key":"key20260417093325_b31-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"3175","DOI":"10.1016\/j.molcel.2024.07.006","article-title":"Nucleosome remodeler exclusion by histone deacetylation enforces heterochromatic silencing and epigenetic inheritance","volume":"84","author":"Sahu","year":"2024","journal-title":"Mol Cell"},{"key":"key20260417093325_b32-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s12094-025-03995-x","article-title":"Clinical progress and functional modalities of HDAC inhibitor-based combination therapies in cancer treatment","volume":"28","author":"Talom","year":"2026","journal-title":"Clin Transl Oncol"},{"key":"key20260417093325_b33-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"4306","DOI":"10.3390\/ijms24054306","article-title":"Histone deacetylases: Molecular mechanisms and therapeutic implications for muscular dystrophies","volume":"24","author":"Sandon\u00e0","year":"2023","journal-title":"Int J Mol Sci"},{"key":"key20260417093325_b34-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/s41586-023-06565-9","article-title":"Acetyl-methyllysine marks chromatin at active transcription start sites","volume":"622","author":"Lu-Culligan","year":"2023","journal-title":"Nature"},{"key":"key20260417093325_b35-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.3390\/ijms25021278","article-title":"EphA2- and HDAC-targeted combination therapy in endometrial cancer","volume":"25","author":"Joseph","year":"2024","journal-title":"Int J Mol Sci"},{"key":"key20260417093325_b36-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1038\/s41375-018-0293-8","article-title":"Combination treatment of acute myeloid leukemia cells with DNMT and HDAC inhibitors: Predominant synergistic gene downregulation associated with gene body demethylation","volume":"33","author":"Blagitko-Dorfs","year":"2019","journal-title":"Leukemia"},{"key":"key20260417093325_b37-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"e2317694121","DOI":"10.1073\/pnas.2317694121","article-title":"Transcriptional repression by HDAC3 mediates T cell exclusion from Kras mutant lung tumors","volume":"121","author":"McGuire","year":"2024","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20260417093325_b38-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"147704","DOI":"10.1016\/j.gene.2023.147704","article-title":"HDACs alters negatively to the tumor immune microenvironment in gynecologic cancers","volume":"885","author":"Yan","year":"2023","journal-title":"Gene"},{"key":"key20260417093325_b39-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1038\/sj.cdd.4401915","article-title":"Activation of NF-kappaB by HDAC inhibitor apicidin through Sp1-dependent de novo protein synthesis: Its implication for resistance to apoptosis","volume":"13","author":"Kim","year":"2006","journal-title":"Cell Death Differ"},{"key":"key20260417093325_b40-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/35042612","article-title":"Deacetylation of p53 modulates its effect on cell growth and apoptosis","volume":"408","author":"Luo","year":"2000","journal-title":"Nature"},{"key":"key20260417093325_b41-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s12032-022-01770-4","article-title":"Differential molecular mechanistic behavior of HDACs in cancer progression","volume":"39","author":"Singh","year":"2022","journal-title":"Med Oncol"},{"key":"key20260417093325_b42-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/s41416-023-02341-8","article-title":"HDAC5 modulates SATB1 transcriptional activity to promote lung adenocarcinoma","volume":"129","author":"Sharma","year":"2023","journal-title":"Br J Cancer"},{"key":"key20260417093325_b43-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"1193637","DOI":"10.3389\/fonc.2023.1193637","article-title":"HDAC-an important target for improving tumor radiotherapy resistance","volume":"13","author":"Ling","year":"2023","journal-title":"Front Oncol"},{"key":"key20260417093325_b44-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"e07904","DOI":"10.1002\/advs.202507904","article-title":"Targeting HDAC and PARP enhances STING-dependent antitumor immunity in STING-deficient tumor","volume":"12","author":"Mao","year":"2025","journal-title":"Adv Sci (Weinh)"},{"key":"key20260417093325_b45-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"8300","DOI":"10.3390\/ijms21218300","article-title":"Priming with HDAC inhibitors sensitizes ovarian cancer cells to treatment with cisplatin and HSP90 inhibitors","volume":"21","author":"Rodrigues Moita","year":"2020","journal-title":"Int J Mol Sci"},{"key":"key20260417093325_b46-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"191","DOI":"10.4196\/kjpp.24.132","article-title":"Tasquinimod promotes the sensitivity of ovarian cancer cells to cisplatin by down-regulating the HDAC4\/p21 pathway","volume":"29","author":"Li","year":"2025","journal-title":"Korean J Physiol Pharmacol"},{"key":"key20260417093325_b47-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.celrep.2016.09.003","article-title":"Loss of HDAC-mediated repression and gain of NF-\u03baB activation underlie cytokine induction in ARID1A- and PIK3CA-mutation-driven ovarian cancer","volume":"17","author":"Kim","year":"2016","journal-title":"Cell Rep"},{"key":"key20260417093325_b48-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"e70120","DOI":"10.1111\/jcmm.70120","article-title":"HDAC7 promotes ovarian cancer malignancy via AKT\/mTOR signalling pathway","volume":"28","author":"Feng","year":"2024","journal-title":"J Cell Mol Med"},{"key":"key20260417093325_b49-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"374","DOI":"10.3390\/biomedicines10020374","article-title":"HDAC9 contributes to serous ovarian cancer progression through regulating epithelial-mesenchymal transition","volume":"10","author":"Xu","year":"2022","journal-title":"Biomedicines"},{"key":"key20260417093325_b50-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"15066","DOI":"10.3390\/ijms242015066","article-title":"The roles of histone deacetylases in the regulation of ovarian cancer metastasis","volume":"24","author":"Xu","year":"2023","journal-title":"Int J Mol Sci"},{"key":"key20260417093325_b51-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.3390\/molecules30132793","article-title":"A novel HDAC6 inhibitor enhances the efficacy of paclitaxel against ovarian cancer cells","volume":"30","author":"Chi","year":"2025","journal-title":"Molecules"},{"key":"key20260417093325_b52-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"3325","DOI":"10.1002\/1878-0261.70050","article-title":"The anticancer effect of the HDAC inhibitor belinostat is enhanced by inhibitors of Bcl-xL or Mcl-1 in ovarian cancer","volume":"19","author":"Thomine","year":"2025","journal-title":"Mol Oncol"},{"key":"key20260417093325_b53-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1007\/s10637-024-01479-3","article-title":"Anti-ovarian cancer migration and toxicity characteristics of a platinum(IV) pro-drug with axial HDAC inhibitor ligands in zebrafish models","volume":"42","author":"Begum","year":"2024","journal-title":"Invest New Drugs"},{"key":"key20260417093325_b54-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"456","DOI":"10.3390\/medicina57050456","article-title":"Effect of the HDAC inhibitor on histone acetylation and methyltransferases in A2780 ovarian cancer cells","volume":"57","author":"Natarajan","year":"2021","journal-title":"Medicina (Kaunas)"},{"key":"key20260417093325_b55-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"1064485","DOI":"10.3389\/fphar.2022.1064485","article-title":"Identification of a novel pyridine derivative with inhibitory activity against ovarian cancer progression in vivo and in vitro","volume":"13","author":"Si","year":"2022","journal-title":"Front Pharmacol"},{"key":"key20260417093325_b56-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"9241","DOI":"10.3390\/ijms25179241","article-title":"Synergistic cytotoxicity of histone deacetylase and poly-ADP ribose polymerase inhibitors and decitabine in breast and ovarian cancer cells: Implications for novel therapeutic combinations","volume":"25","author":"Valdez","year":"2024","journal-title":"Int J Mol Sci"},{"key":"key20260417093325_b57-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"e2309755","DOI":"10.1002\/advs.202309755","article-title":"Dissecting the distinct tumor microenvironments of HRD and HRP ovarian cancer: Implications for targeted therapies to overcome PARPi resistance in HRD tumors and refractoriness in HRP tumors","volume":"11","author":"Qiu","year":"2024","journal-title":"Adv Sci (Weinh)"},{"key":"key20260417093325_b58-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s00280-023-04610-y","article-title":"CUDC-907 exhibits potent antitumor effects against ovarian cancer through multiple in vivo and in vitro mechanisms","volume":"93","author":"Wang","year":"2024","journal-title":"Cancer Chemother Pharmacol"},{"key":"key20260417093325_b59-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"3576","DOI":"10.1038\/s41598-020-60271-4","article-title":"HDAC6, modulated by miR-206, promotes endometrial cancer progression through the PTEN\/AKT\/mTOR pathway","volume":"10","author":"Zheng","year":"2020","journal-title":"Sci Rep"},{"key":"key20260417093325_b60-ol-31-4-15497","first-page":"5029","article-title":"Enhancing progestin therapy via HDAC inhibitors in endometrial cancer","volume":"12","author":"Li","year":"2022","journal-title":"Am J Cancer Res"},{"key":"key20260417093325_b61-ol-31-4-15497","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-25-0544","article-title":"MIG-6 regulates HDAC1-mediated angiogenesis and tumorigenesis in PTEN-deficient endometrioid endometrial cancer","author":"Nahar","year":"2026","journal-title":"Mol Cancer Res"},{"key":"key20260417093325_b62-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"7850688","DOI":"10.1155\/2021\/7850688","article-title":"Histone deacetylase inhibitors: A promising therapeutic alternative for endometrial carcinoma","volume":"2021","author":"Psilopatis","year":"2021","journal-title":"Dis Markers"},{"key":"key20260417093325_b63-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"4032","DOI":"10.3390\/cancers13164032","article-title":"Hyaluronic acid-functionalized nanomicelles enhance SAHA efficacy in 3D endometrial cancer models","volume":"13","author":"Edwards","year":"2021","journal-title":"Cancers (Basel)"},{"key":"key20260417093325_b64-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.ygyno.2024.07.682","article-title":"A phase 2 feasibility study of nab-paclitaxel and carboplatin in epithelial carcinoma of the uterus","volume":"190","author":"Pothuri","year":"2024","journal-title":"Gynecol Oncol"},{"key":"key20260417093325_b65-ol-31-4-15497","first-page":"160","article-title":"Mechanisms of cisplatin in combination with repurposed drugs against human endometrial carcinoma cells","volume":"11","author":"Lin","year":"2021","journal-title":"Life (Basel)"},{"key":"key20260417093325_b66-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"721721","DOI":"10.3892\/ol.2021.12982","article-title":"Histone deacetylase 1 facilitates aerobic glycolysis and growth of endometrial cancer","volume":"22","author":"Wu","year":"2021","journal-title":"Oncol Lett"},{"key":"key20260417093325_b67-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"1432131","DOI":"10.3389\/or.2024.1432131","article-title":"Research progress on the mechanism of histone deacetylases in ferroptosis of glioma","volume":"18","author":"Ma","year":"2024","journal-title":"Oncol Rev"},{"key":"key20260417093325_b68-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"103030","DOI":"10.1016\/j.redox.2024.103030","article-title":"SIRT1 activated by AROS sensitizes glioma cells to ferroptosis via induction of NAD+ depletion-dependent activation of ATF3","volume":"69","author":"Chen","year":"2024","journal-title":"Redox Biol"},{"key":"key20260417093325_b69-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s40478-025-02194-7","article-title":"Targeting glioblastoma with HDAC inhibitors: Insights into hydroxamic acid-based therapeutic strategies","volume":"14","author":"Pai","year":"2025","journal-title":"Acta Neuropathol Commun"},{"key":"key20260417093325_b70-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"6233","DOI":"10.1158\/0008-5472.CAN-21-1547","article-title":"A dual PI3K\/HDAC inhibitor induces immunogenic ferroptosis to potentiate cancer immune checkpoint therapy","volume":"81","author":"Fan","year":"2021","journal-title":"Cancer Res"},{"key":"key20260417093325_b71-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.1002\/glia.24065","article-title":"Histone-deacetylase 8 drives the immune response and the growth of glioma","volume":"69","author":"Mormino","year":"2021","journal-title":"Glia"},{"key":"key20260417093325_b72-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"963689720981878","DOI":"10.1177\/0963689720981878","article-title":"Valproic acid enhanced apoptosis by promoting autophagy via Akt\/mTOR signaling in glioma","volume":"29","author":"Han","year":"2020","journal-title":"Cell Transplant"},{"key":"key20260417093325_b73-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"35004","DOI":"10.18632\/oncotarget.5253","article-title":"Valproic acid enhances the efficacy of radiation therapy by protecting normal hippocampal neurons and sensitizing malignant glioblastoma cells","volume":"6","author":"Thotala","year":"2015","journal-title":"Oncotarget"},{"key":"key20260417093325_b74-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1021\/acs.jmedchem.1c01726","article-title":"N-methylpropargylamine-conjugated hydroxamic acids as dual inhibitors of monoamine oxidase A and histone deacetylase for glioma treatment","volume":"65","author":"Mehndiratta","year":"2022","journal-title":"J Med Chem"},{"key":"key20260417093325_b75-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"107721","DOI":"10.1016\/j.pharmthera.2020.107721","article-title":"Targeting post-translational histone modifying enzymes in glioblastoma","volume":"220","author":"Kunadis","year":"2021","journal-title":"Pharmacol Ther"},{"key":"key20260417093325_b76-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s12032-025-02760-y","article-title":"Epigenetic reprogramming and antitumor immune responses in gliomas: A systematic review","volume":"42","author":"Riyas Mohamed","year":"2025","journal-title":"Med Oncol"},{"key":"key20260417093325_b77-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.3390\/cancers15041342","article-title":"DNA methylation and histone modification in low-grade gliomas: Current understanding and potential clinical targets","volume":"15","author":"Ozair","year":"2023","journal-title":"Cancers (Basel)"},{"key":"key20260417093325_b78-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1002\/ijc.34027","article-title":"A synergistic interaction between HDAC- and PARP inhibitors in childhood tumors with chromothripsis","volume":"151","author":"Khalid","year":"2022","journal-title":"Int J Cancer"},{"key":"key20260417093325_b79-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1007\/s10565-021-09651-8","article-title":"ERR\u03b1 contributes to HDAC6-induced chemoresistance of osteosarcoma cells","volume":"39","author":"He","year":"2023","journal-title":"Cell Biol Toxicol"},{"key":"key20260417093325_b80-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1177\/1933719111398147","article-title":"Histone deacetylase 6 regulates estrogen receptor alpha in uterine leiomyoma","volume":"18","author":"Wei","year":"2011","journal-title":"Reprod Sci"},{"key":"key20260417093325_b81-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"4426","DOI":"10.1021\/acs.jmedchem.4c02373","article-title":"Exploring alternative zinc-binding groups in histone deacetylase (HDAC) inhibitors uncovers DS-103 as a potent ethylhydrazide-based HDAC inhibitor with chemosensitizing properties","volume":"68","author":"Stopper","year":"2025","journal-title":"J Med Chem"},{"key":"key20260417093325_b82-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1182\/blood.2019003538","article-title":"FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia","volume":"135","author":"Long","year":"2020","journal-title":"Blood"},{"key":"key20260417093325_b83-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1002\/ijc.33046","article-title":"Histone deacetylase inhibition prevents the growth of primary and metastatic osteosarcoma","volume":"147","author":"McGuire","year":"2020","journal-title":"Int J Cancer"},{"key":"key20260417093325_b84-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.21873\/anticanres.16421","article-title":"Sodium valproate enhances semaphorin 3A-mediated anti-angiogenesis and tumor growth inhibition in human osteosarcoma cells","volume":"43","author":"Sawai","year":"2023","journal-title":"Anticancer Res"},{"key":"key20260417093325_b85-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"109489","DOI":"10.1016\/j.abb.2022.109489","article-title":"Anti-proliferative, pro-apototic and anti-migratory properties of HDAC inhibitor PXD-101 on osteosarcoma cell lines","volume":"734","author":"Rossi","year":"2023","journal-title":"Arch Biochem Biophys"},{"key":"key20260417093325_b86-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.3390\/ijms26083574","article-title":"Synergistic HDAC4\/8 inhibition sensitizes osteosarcoma to doxorubicin via pAKT\/RUNX2 pathway modulation","volume":"26","author":"Magar","year":"2025","journal-title":"Int J Mol Sci"},{"key":"key20260417093325_b87-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/978-3-030-43085-6_4","article-title":"Targeting the cancer epigenome with histone deacetylase inhibitors in osteosarcoma","volume":"1258","author":"Collier","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"key20260417093325_b88-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1016\/j.medj.2024.07.007","article-title":"A prospective phase 2 study of combination epigenetic therapy against relapsed\/refractory peripheral T cell lymphoma","volume":"5","author":"Ding","year":"2024","journal-title":"Med"},{"key":"key20260417093325_b89-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s40164-024-00507-5","article-title":"Exploring the role of histone deacetylase and histone deacetylase inhibitors in the context of multiple myeloma: Mechanisms, therapeutic implications, and future perspectives","volume":"13","author":"Pu","year":"2024","journal-title":"Exp Hematol Oncol"},{"key":"key20260417093325_b90-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1186\/s12964-025-02198-9","article-title":"ER-phagy mediates the anti-tumoral synergism between HDAC inhibition and chemotherapy","volume":"23","author":"G\u00f6ssl","year":"2025","journal-title":"Cell Commun Signal"},{"key":"key20260417093325_b91-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"e010077","DOI":"10.1136\/jitc-2024-010077","article-title":"HDAC inhibitor SAHA enhances antitumor immunity via the HDAC1\/JAK1\/FGL1 axis in lung adenocarcinoma","volume":"12","author":"Xu","year":"2024","journal-title":"J Immunother Cancer"},{"key":"key20260417093325_b92-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.3390\/molecules28031456","article-title":"Entinostat-bortezomib hybrids against multiple myeloma","volume":"28","author":"Ferro","year":"2023","journal-title":"Molecules"},{"key":"key20260417093325_b93-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s13046-021-01909-7","article-title":"Small-molecule HDAC and Akt inhibitors suppress tumor growth and enhance immunotherapy in multiple myeloma","volume":"40","author":"Hirano","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"key20260417093325_b94-ol-31-4-15497","first-page":"784","article-title":"HDAC6 inhibitors sensitize resistant t(11;14) multiple myeloma cells to a combination of bortezomib and BH3 mimetics","volume":"110","author":"Florean","year":"2025","journal-title":"Haematologica"},{"key":"key20260417093325_b95-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41375-020-0840-y","article-title":"Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab","volume":"35","author":"Garc\u00eda-Guerrero","year":"2021","journal-title":"Leukemia"},{"key":"key20260417093325_b96-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s41389-020-0234-z","article-title":"USP38 regulates the stemness and chemoresistance of human colorectal cancer via regulation of HDAC3","volume":"9","author":"Zhan","year":"2020","journal-title":"Oncogenesis"},{"key":"key20260417093325_b97-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1101\/gad.333674.119","article-title":"HDAC3 ensures stepwise epidermal stratification via NCoR\/SMRT-reliant mechanisms independent of its histone deacetylase activity","volume":"34","author":"Szigety","year":"2020","journal-title":"Genes Dev"},{"key":"key20260417093325_b98-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1038\/s41418-023-01139-8","article-title":"Targeting HDAC3 to overcome the resistance to ATRA or arsenic in acute promyelocytic leukemia through ubiquitination and degradation of PML-RAR\u03b1","volume":"30","author":"Dai","year":"2023","journal-title":"Cell Death Differ"},{"key":"key20260417093325_b99-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1158\/2326-6066.CIR-22-0317","article-title":"HDAC3 inhibition promotes antitumor immunity by enhancing CXCL10-mediated chemotaxis and recruiting of immune cells","volume":"11","author":"Li","year":"2023","journal-title":"Cancer Immunol Res"},{"key":"key20260417093325_b100-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"182","DOI":"10.3390\/vaccines13020182","article-title":"HDAC3: A multifaceted modulator in immunotherapy sensitization","volume":"13","author":"Han","year":"2025","journal-title":"Vaccines (Basel)"},{"key":"key20260417093325_b101-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"eadd3243","DOI":"10.1126\/sciadv.add3243","article-title":"HDAC3 is critical in tumor development and therapeutic resistance in Kras-mutant non-small cell lung cancer","volume":"9","author":"Eichner","year":"2023","journal-title":"Sci Adv"},{"key":"key20260417093325_b102-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"3904","DOI":"10.1007\/s10528-023-10621-4","article-title":"Enterotoxigenic bacteroides fragilis (ETBF) enhances colorectal cancer cell proliferation and metastasis through HDAC3\/miR-139-3p pathway","volume":"62","author":"Wu","year":"2024","journal-title":"Biochem Genet"},{"key":"key20260417093325_b103-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/s41420-024-02115-y","article-title":"HDAC3 genetic and pharmacologic inhibition radiosensitizes fusion positive rhabdomyosarcoma by promoting DNA double-strand breaks","volume":"10","author":"Cassandri","year":"2024","journal-title":"Cell Death Discov"},{"key":"key20260417093325_b104-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1158\/0008-5472.CAN-20-2828","article-title":"HDAC5 loss impairs RB repression of pro-oncogenic genes and confers CDK4\/6 inhibitor resistance in cancer","volume":"81","author":"Zhou","year":"2021","journal-title":"Cancer Res"},{"key":"key20260417093325_b105-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"11523","DOI":"10.1007\/s13277-014-2358-2","article-title":"Down-regulation of HDAC5 inhibits growth of human hepatocellular carcinoma by induction of apoptosis and cell cycle arrest","volume":"35","author":"Fan","year":"2014","journal-title":"Tumour Biol"},{"key":"key20260417093325_b106-ol-31-4-15497","first-page":"102016","article-title":"HDAC5, an early osimertinib-responsive gene, is a novel therapeutic target for the drug resistance in EGFR-mutant lung adenocarcinoma cells","volume":"42","author":"Lyu","year":"2025","journal-title":"Biochem Biophys Rep"},{"key":"key20260417093325_b107-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"4542","DOI":"10.1158\/0008-5472.CAN-21-4362","article-title":"HDAC5 loss enhances phospholipid-derived arachidonic acid generation and confers sensitivity to cPLA2 inhibition in pancreatic cancer","volume":"82","author":"Pan","year":"2022","journal-title":"Cancer Res"},{"key":"key20260417093325_b108-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"1327933","DOI":"10.3389\/fonc.2024.1327933","article-title":"HDAC7: A promising target in cancer","volume":"14","author":"Liu","year":"2024","journal-title":"Front Oncol"},{"key":"key20260417093325_b109-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"e576","DOI":"10.1002\/mco2.576","article-title":"Tweety homolog 3 promotes colorectal cancer progression through mutual regulation of histone deacetylase 7","volume":"5","author":"Lu","year":"2024","journal-title":"MedComm (2020)"},{"key":"key20260417093325_b110-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/07391102.2024.2437523","article-title":"Characterization of molecular interactions between HDAC7 and MEF2A","author":"Gautam","year":"2024","journal-title":"J Biomol Struct Dyn"},{"key":"key20260417093325_b111-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"e34577","DOI":"10.1097\/MD.0000000000034577","article-title":"Comprehensive analysis of HDAC7 expression and its prognostic value in diffuse large B cell lymphoma: A review","volume":"102","author":"Lu","year":"2023","journal-title":"Medicine (Baltimore)"},{"key":"key20260417093325_b112-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1016\/j.apsb.2025.01.021","article-title":"Discovery of a potential hematologic malignancies therapy: Selective and potent HDAC7 PROTAC degrader targeting non-enzymatic function","volume":"15","author":"Jin","year":"2025","journal-title":"Acta Pharm Sin B"},{"key":"key20260417093325_b113-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1158\/0008-5472.CAN-20-3044","article-title":"HDAC11 regulates glycolysis through the LKB1\/AMPK signaling pathway to maintain hepatocellular carcinoma stemness","volume":"81","author":"Bi","year":"2021","journal-title":"Cancer Res"},{"key":"key20260417093325_b114-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"724","DOI":"10.3389\/fcell.2020.00724","article-title":"Promoter hypomethylation and miR-145-5p downregulation-mediated HDAC11 overexpression promotes sorafenib resistance and metastasis of hepatocellular carcinoma cells","volume":"8","author":"Wang","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"key20260417093325_b115-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"115418","DOI":"10.1016\/j.biopha.2023.115418","article-title":"HDAC11: A novel target for improved cancer therapy","volume":"166","author":"Liu","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"key20260417093325_b116-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1002\/JLB.1A1119-606RRR","article-title":"HDAC11 regulates expression of C\/EBP\u03b2 and immunosuppressive molecules in myeloid-derived suppressor cells","volume":"109","author":"Chen","year":"2021","journal-title":"J Leukoc Biol"},{"key":"key20260417093325_b117-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/ni.1673","article-title":"The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance","volume":"10","author":"Villagra","year":"2009","journal-title":"Nat Immunol"},{"key":"key20260417093325_b118-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"e22326","DOI":"10.1096\/fj.202101742RR","article-title":"A pan-cancer analysis identifies HDAC11 as an immunological and prognostic biomarker","volume":"36","author":"Li","year":"2022","journal-title":"FASEB J"},{"key":"key20260417093325_b119-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1080\/13543776.2020.1725470","article-title":"Histone deacetylase (HDAC) inhibitors in cancer: A patent review (2017-present)","volume":"30","author":"Zhao","year":"2020","journal-title":"Expert Opin Ther Pat"},{"key":"key20260417093325_b120-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.semcancer.2020.11.005","article-title":"Anticancer properties of chimeric HDAC and kinase inhibitors","volume":"83","author":"Biersack","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"key20260417093325_b121-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"105220","DOI":"10.1016\/j.jbc.2023.105220","article-title":"Inhibition of mitochondrial fatty acid \u03b2-oxidation activates mTORC1 pathway and protein synthesis via Gcn5-dependent acetylation of raptor in zebrafish","volume":"299","author":"Zhou","year":"2023","journal-title":"J Biol Chem"},{"key":"key20260417093325_b122-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"11672","DOI":"10.1021\/acs.jmedchem.3c01160","article-title":"Evolution of slow-binding inhibitors targeting histone deacetylase isoforms","volume":"66","author":"Mukherjee","year":"2023","journal-title":"J Med Chem"},{"key":"key20260417093325_b123-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/S1470-2045(14)70440-1","article-title":"Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: A multicentre, randomised, double-blind phase 3 trial","volume":"15","author":"San-Miguel","year":"2014","journal-title":"Lancet Oncol"},{"key":"key20260417093325_b124-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"9073","DOI":"10.18632\/oncotarget.3268","article-title":"Dual inhibition of HDAC and EGFR signaling with CUDC-101 induces potent suppression of tumor growth and metastasis in anaplastic thyroid cancer","volume":"6","author":"Zhang","year":"2015","journal-title":"Oncotarget"},{"key":"key20260417093325_b125-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"5570","DOI":"10.1038\/s41467-024-49784-y","article-title":"Epigenetic-based differentiation therapy for acute myeloid leukemia","volume":"15","author":"San Jos\u00e9-En\u00e9riz","year":"2024","journal-title":"Nat Commun"},{"key":"key20260417093325_b126-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.3748\/wjg.v28.i18.1934","article-title":"Targeting pancreatic cancer immune evasion by inhibiting histone deacetylases","volume":"28","author":"Sim","year":"2022","journal-title":"World J Gastroenterol"},{"key":"key20260417093325_b127-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1016\/j.ccell.2023.06.010","article-title":"Loss of SYNCRIP unleashes APOBEC-driven mutagenesis, tumor heterogeneity, and AR-targeted therapy resistance in prostate cancer","volume":"41","author":"Li","year":"2023","journal-title":"Cancer Cell"},{"key":"key20260417093325_b128-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41392-025-02285-w","article-title":"Preclinical and first-in-human of purinostat mesylate, a novel selective HDAC I\/IIb inhibitor, in relapsed\/refractory multiple myeloma and lymphoma","volume":"10","author":"Yang","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"key20260417093325_b129-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"3658","DOI":"10.1182\/blood-2010-11-318055","article-title":"Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor-induced thrombocytopenia","volume":"117","author":"Bishton","year":"2011","journal-title":"Blood"},{"key":"key20260417093325_b130-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1080\/13543776.2023.2219394","article-title":"An updated patent review of histone deacetylase (HDAC) inhibitors in cancer (2020-present)","volume":"33","author":"Liu","year":"2023","journal-title":"Expert Opin Ther Pat"},{"key":"key20260417093325_b131-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1093\/jmcb\/mjy066","article-title":"The HDAC3 enzymatic activity regulates skeletal muscle fuel metabolism","volume":"11","author":"Song","year":"2019","journal-title":"J Mol Cell Biol"},{"key":"key20260417093325_b132-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"968","DOI":"10.3390\/ph16070968","article-title":"Application of ligand- and structure-based prediction models for the design of alkylhydrazide-based HDAC3 inhibitors as novel anti-cancer compounds","volume":"16","author":"B\u00fclb\u00fcl","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"key":"key20260417093325_b133-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"7468","DOI":"10.1021\/acs.jmedchem.1c00136","article-title":"Discovery of STAT3 and histone deacetylase (HDAC) dual-pathway inhibitors for the treatment of solid cancer","volume":"64","author":"Ren","year":"2021","journal-title":"J Med Chem"},{"key":"key20260417093325_b134-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/s41586-024-08533-3","article-title":"Converging mechanism of UM171 and KBTBD4 neomorphic cancer mutations","volume":"639","author":"Xie","year":"2025","journal-title":"Nature"},{"key":"key20260417093325_b135-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"4318","DOI":"10.1038\/s41467-022-32050-4","article-title":"Engineered bioorthogonal POLY-PROTAC nanoparticles for tumour-specific protein degradation and precise cancer therapy","volume":"13","author":"Gao","year":"2022","journal-title":"Nat Commun"},{"key":"key20260417093325_b136-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1007\/s10565-023-09823-8","article-title":"Trps1 acts as a regulator of Sf-1 transcription and testosterone synthesis in mouse Leydig cells","volume":"39","author":"Sun","year":"2023","journal-title":"Cell Biol Toxicol"},{"key":"key20260417093325_b137-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"e2307818","DOI":"10.1002\/adma.202307818","article-title":"An \u2018AND\u2019 logic-gated prodrug micelle locally stimulates antitumor immunity","volume":"36","author":"Chen","year":"2024","journal-title":"Adv Mater"},{"key":"key20260417093325_b138-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"e2104359","DOI":"10.1002\/smll.202170248","article-title":"Bioswitchable delivery of microRNA by framework nucleic acids: Application to bone regeneration","volume":"17","author":"Li","year":"2021","journal-title":"Small"},{"key":"key20260417093325_b139-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"113469","DOI":"10.1016\/j.colsurfb.2023.113469","article-title":"Tracking intracellular nuclear targeted-chemotherapy of chidamide-loaded Prussian blue nanocarriers by SERS mapping","volume":"229","author":"Xing","year":"2023","journal-title":"Colloids Surf B Biointerfaces"},{"key":"key20260417093325_b140-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s00408-025-00798-3","article-title":"The role of HDAC3 in pulmonary diseases","volume":"203","author":"Hong","year":"2025","journal-title":"Lung"},{"key":"key20260417093325_b141-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"e2412903","DOI":"10.1002\/advs.202412903","article-title":"Targeting histone deacetylase 11 with a highly selective inhibitor for the treatment of MASLD","volume":"12","author":"Zhang","year":"2025","journal-title":"Adv Sci (Weinh)"},{"key":"key20260417093325_b142-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"948217","DOI":"10.3389\/fchem.2022.948217","article-title":"Potential of histone deacetylase inhibitors in the control and regulation of prostate, breast and ovarian cancer","volume":"10","author":"Pramanik","year":"2022","journal-title":"Front Chem"},{"key":"key20260417093325_b143-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1158\/2326-6066.CIR-15-0077-T","article-title":"HDAC inhibition upregulates PD-1 ligands in melanoma and augments immunotherapy with PD-1 blockade","volume":"3","author":"Woods","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"key20260417093325_b144-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"e151002","DOI":"10.1172\/JCI151002","article-title":"Epigenetic modifiers synergize with immune-checkpoint blockade to enhance long-lasting antitumor efficacy","volume":"131","author":"Baretti","year":"2021","journal-title":"J Clin Invest"},{"key":"key20260417093325_b145-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"4104","DOI":"10.1158\/1078-0432.CCR-12-0055","article-title":"Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling","volume":"18","author":"Qian","year":"2012","journal-title":"Clin Cancer Res"},{"key":"key20260417093325_b146-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"107205","DOI":"10.1016\/j.phrs.2024.107205","article-title":"Epigenetic modulations in triple-negative breast cancer: Therapeutic implications for tumor microenvironment","volume":"204","author":"Zhou","year":"2024","journal-title":"Pharmacol Res"},{"key":"key20260417093325_b147-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"4708","DOI":"10.3390\/cancers14194708","article-title":"Histone deacetylase inhibitors as a therapeutic strategy to eliminate neoplastic \u2018stromal\u2019 cells from giant cell tumors of bone","volume":"14","author":"Venneker","year":"2022","journal-title":"Cancers (Basel)"},{"key":"key20260417093325_b148-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"1057186","DOI":"10.3389\/fonc.2022.1057186","article-title":"Potential of histone deacetylase inhibitors for the therapy of ovarian cancer","volume":"12","author":"Guo","year":"2022","journal-title":"Front Oncol"},{"key":"key20260417093325_b149-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1038\/s41388-020-01636-x","article-title":"HDAC inhibition potentiates anti-tumor activity of macrophages and enhances anti-PD-L1-mediated tumor suppression","volume":"40","author":"Li","year":"2021","journal-title":"Oncogene"},{"key":"key20260417093325_b150-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"e159283","DOI":"10.1172\/JCI159283","article-title":"HDACi promotes inflammatory remodeling of the tumor microenvironment to enhance epitope spreading and antitumor immunity","volume":"132","author":"Nguyen","year":"2022","journal-title":"J Clin Invest"},{"key":"key20260417093325_b151-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s40001-025-02326-8","article-title":"Targeted intervention of tumor microenvironment with HDAC inhibitors and their combination therapy strategies","volume":"30","author":"Zhang","year":"2025","journal-title":"Eur J Med Res"},{"key":"key20260417093325_b152-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41392-022-01274-7","article-title":"Diffuse midline glioma treated with epigenetic agent-based immunotherapy","volume":"8","author":"Jing","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"key20260417093325_b153-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1158\/2159-8290.CD-20-1065","article-title":"Endogenous retroelement activation by epigenetic therapy reverses the warburg effect and elicits mitochondrial-mediated cancer cell death","volume":"11","author":"Fresquet","year":"2021","journal-title":"Cancer Discov"},{"key":"key20260417093325_b154-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"634","DOI":"10.3390\/cancers13040634","article-title":"Anticancer therapy with HDAC inhibitors: Mechanism-based combination strategies and future perspectives","volume":"13","author":"Jenke","year":"2021","journal-title":"Cancers (Basel)"},{"key":"key20260417093325_b155-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"8530","DOI":"10.2174\/0109298673332285241104091609","article-title":"Structural modifications and prospects of histone deacetylase (HDAC) inhibitors in cancer","volume":"32","author":"Chen","year":"2025","journal-title":"Curr Med Chem"},{"key":"key20260417093325_b156-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"e70919","DOI":"10.1002\/cam4.70919","article-title":"Chidamide, a histone deacetylase inhibitor, combined with R-GemOx in relapsed\/refractory diffuse large B-cell lymphoma (TRUST): A multicenter, single-arm, phase 2 trial","volume":"14","author":"Zou","year":"2025","journal-title":"Cancer Med"},{"key":"key20260417093325_b157-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"oyaf155","DOI":"10.1093\/oncolo\/oyaf155","article-title":"First-line treatment with HDACis plus tislelizumab combined with chemotherapy in advanced NSCLC: A single-arm phase II study","volume":"30","author":"Wang","year":"2025","journal-title":"Oncologist"},{"key":"key20260417093325_b158-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"4917","DOI":"10.1158\/1078-0432.CCR-19-0171","article-title":"Histone deacetylase inhibition with panobinostat combined with intensive induction chemotherapy in older patients with acute myeloid leukemia: Phase I study results","volume":"25","author":"Wieduwilt","year":"2019","journal-title":"Clin Cancer Res"},{"key":"key20260417093325_b159-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s40164-023-00383-5","article-title":"Synergistic effect of HDAC inhibitor chidamide with cladribine on cell cycle arrest and apoptosis by targeting HDAC2\/c-Myc\/RCC1 axis in acute myeloid leukemia","volume":"12","author":"Gu","year":"2023","journal-title":"Exp Hematol Oncol"},{"key":"key20260417093325_b160-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"e2411053","DOI":"10.1002\/advs.202411053","article-title":"CK2B induces CD8+ T-cell exhaustion through HDAC8-mediated epigenetic reprogramming to limit the efficacy of anti-PD-1 therapy in non-small-cell lung cancer","volume":"12","author":"Liu","year":"2025","journal-title":"Adv Sci (Weinh)"},{"key":"key20260417093325_b161-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"3667","DOI":"10.1021\/acs.jmedchem.1c02225","article-title":"Discovery of DNA-targeting HDAC inhibitors with potent antitumor efficacy in vivo that trigger antitumor immunity","volume":"65","author":"Chen","year":"2022","journal-title":"J Med Chem"},{"key":"key20260417093325_b162-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1186\/s12951-024-02936-0","article-title":"HDACi combination therapy with IDO1i remodels the tumor microenvironment and boosts antitumor efficacy in colorectal cancer with microsatellite stability","volume":"22","author":"Liang","year":"2024","journal-title":"J Nanobiotechnology"},{"key":"key20260417093325_b163-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/nature21409","article-title":"Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages","volume":"543","author":"Guerriero","year":"2017","journal-title":"Nature"},{"key":"key20260417093325_b164-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1038\/s41586-025-08795-5","article-title":"Genome-wide CRISPR screen in human T cells reveals regulators of FOXP3","volume":"642","author":"Chen","year":"2025","journal-title":"Nature"},{"key":"key20260417093325_b165-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"104801","DOI":"10.1016\/j.bioorg.2021.104801","article-title":"Discovery of novel tetrahydrobenzo[b]thiophene-3-carbonitriles as histone deacetylase inhibitors","volume":"110","author":"Gediya","year":"2021","journal-title":"Bioorg Chem"},{"key":"key20260417093325_b166-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"107937","DOI":"10.1016\/j.jmgm.2021.107937","article-title":"Discovery of novel isoform-selective histone deacetylases 5 and 9 inhibitors through combined ligand-based pharmacophore modeling, molecular mocking, and molecular dynamics simulations for cancer treatment","volume":"106","author":"Elmezayen","year":"2021","journal-title":"J Mol Graph Model"},{"key":"key20260417093325_b167-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"130214","DOI":"10.1016\/j.bmcl.2025.130214","article-title":"Synthesis and biological evaluation of novel 4-Arylaminoquinolines derivatives as EGFR\/HDAC inhibitors","volume":"122","author":"Yao","year":"2025","journal-title":"Bioorg Med Chem Lett"},{"key":"key20260417093325_b168-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"105166","DOI":"10.1016\/j.oraloncology.2020.105166","article-title":"Synergistic efficacy of combined EGFR and HDAC inhibitors overcomes tolerance to EGFR monotherapy in salivary mucoepidermoid carcinoma","volume":"115","author":"Parag-Sharma","year":"2021","journal-title":"Oral Oncol"},{"key":"key20260417093325_b169-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"4991","DOI":"10.3390\/molecules25214991","article-title":"Development of a bestatin-SAHA hybrid with dual inhibitory activity against APN and HDAC","volume":"25","author":"Cao","year":"2020","journal-title":"Molecules"},{"key":"key20260417093325_b170-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"1529239","DOI":"10.3389\/fimmu.2025.1529239","article-title":"Mechanisms of HDACs in cancer development","volume":"16","author":"Zhang","year":"2025","journal-title":"Front Immunol"},{"key":"key20260417093325_b171-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"175216","DOI":"10.1016\/j.ejphar.2022.175216","article-title":"The emerging roles of HDACs and their therapeutic implications in cancer","volume":"931","author":"Hai","year":"2022","journal-title":"Eur J Pharmacol"},{"key":"key20260417093325_b172-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"63","DOI":"10.4103\/abr.abr_142_19","article-title":"Histone deacetylases and histone deacetylase inhibitors: Molecular mechanisms of action in various cancers","volume":"8","author":"Sanaei","year":"2019","journal-title":"Adv Biomed Res"},{"key":"key20260417093325_b173-ol-31-4-15497","article-title":"HDAC6: Tumor progression and beyond","author":"Oliveira-Silva","year":"2025","journal-title":"Curr Cancer Drug Targets"},{"key":"key20260417093325_b174-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"9592","DOI":"10.3390\/ijms23179592","article-title":"Targeting HDAC6 to overcome autophagy-promoted anti-cancer drug resistance","volume":"23","author":"Jo","year":"2022","journal-title":"Int J Mol Sci"},{"key":"key20260417093325_b175-ol-31-4-15497","doi-asserted-by":"publisher","first-page":"e2309459","DOI":"10.1002\/advs.202309459","article-title":"PROTAC-mediated HDAC7 protein degradation unveils its deacetylase-independent proinflammatory function in macrophages","volume":"11","author":"Kadier","year":"2024","journal-title":"Adv Sci (Weinh)"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T06:33:37Z","timestamp":1776407617000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2026.15497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,24]]},"references-count":175,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,2,24]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2026.15497","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,24]]}}}